The recommendation levels in the CSCO (Chinese Society of Clinical Oncology) guidelines serve as a bridge connecting high-level medical evidence with complex clinical decisions. These levels are not simple classifications but are determined by comprehensively evaluating the strength of evidence, drug accessibility, and expert consensus. They directly influence which treatment regimens are used in clinical practice and their order of priority.
The CSCO guidelines primarily categorize recommendations into three levels. A Level I recommendation represents the standard treatment that should be prioritized for patients under current conditions, indicating a mature regimen with confirmed efficacy that is affordable and accessible to most patients. A Level II recommendation signifies either high-level evidence with slightly lower accessibility, or slightly lower evidence levels but high expert consensus. A Level III recommendation indicates lower evidence levels, but the treatment is commonly used in clinical practice, holds exploratory value, and is considered acceptable by experts.
In the era of evidence-based medicine for cancer diagnosis and treatment, the CSCO guidelines are not only a pocket guide for clinicians but also a touchstone for evaluating the value of innovative drugs. Recently, Allist Pharmaceuticals announced that the application status for the marketing authorization of Fumeitinib Mesylate Tablets for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations has been updated to "approval completed - awaiting certificate issuance." By analyzing the diagnostic and therapeutic pathway outlined in the CSCO guidelines, we can assess the drug's potential clinical positioning, market access prospects, and its strategy for breaking into a competitive market.
EGFR exon 20 insertion mutations are a common subtype among EGFR-mutated NSCLC cases, accounting for approximately 2% to 5% of EGFR-mutant NSCLC patients in China. Compared to patients with common EGFR mutations, those with EGFR exon 20 insertion mutations typically have a poorer prognosis.
Specifically, patients with EGFR exon 20 insertion mutations face a 75% higher risk of death compared to those with common EGFR mutations. The median overall survival (mOS) for the former is 16.2 months, while it can reach 25.5 months for the latter. Furthermore, patients with EGFR exon 20 insertion mutations have a 93% increased risk of disease progression or death, reflected in a median progression-free survival (mPFS) of just 5.1 months, compared to an mPFS of 10.3 months for patients with common EGFR mutations.
For patients with advanced/metastatic NSCLC harboring EGFR exon 20 insertion mutations, the "Chinese Society of Clinical Oncology Non-Small Cell Lung Cancer Guidelines 2025" recommends amivantamab in combination with chemotherapy as a Level I, first-line treatment option. In the Chinese Phase II single-arm registration study WUKONG6, Sunvozertinib achieved an objective response rate (ORR) of 61% in the overall population with EGFR exon 20 insertion mutations. Based on this, the NMPA has approved Sunvozertinib for the treatment of locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutations who have progressed on or are intolerant to platinum-based chemotherapy, and it is listed as a Level I recommendation.
Beyond this, the Level II recommendations for this indication refer to later-line treatment regimens used for NSCLC without driver genes, indicating relatively limited treatment options. Allist's Fumeitinib is also targeting second-line treatment for NSCLC with EGFR exon 20 insertion mutations, positioning it in direct competition with Sunvozertinib.
Data shows that in a Phase II clinical study involving previously treated NSCLC patients with EGFR exon 20 insertion mutations, Fumeitinib demonstrated a confirmed objective response rate (ORR) of 44.3%, a median progression-free survival (mPFS) of 8.3 months, and a median overall survival (OS) of 22.9 months.
In a non-head-to-head comparison, Sunvozertinib's ORR in second-line treatment is 61%, which is higher than Fumeitinib's. However, its mPFS is 6.5 months, lower than that of Fumeitinib. Based on existing data, Fumeitinib shows robust efficacy in previously treated patients with EGFR exon 20 insertion mutations, particularly demonstrating a potential advantage over Sunvozertinib in terms of progression-free survival.
Although its ORR is slightly lower than Sunvozertinib's, Fumeitinib's longer mPFS and median OS approaching two years suggest it possesses differentiated advantages in controlling disease progression and prolonging survival, potentially allowing it to carve out a complementary role in clinical practice. However, the current data still comes from a Phase II single-arm study with a limited sample size and no control group. If subsequent larger confirmatory studies fail to validate these survival benefits, Fumeitinib's recommendation level in the CSCO guidelines could be constrained.
From a competitive landscape perspective, the second-line treatment space for EGFR exon 20 insertion mutations is currently dominated by Sunvozertinib. More critically, on March 22, Dizal Pharmaceutical announced positive top-line results from the Phase III clinical trial of Sunvozertinib as a first-line treatment for EGFR exon 20 insertion mutation NSCLC. This impending expansion of its indication into the first-line setting further consolidates Sunvozertinib's comprehensive dominance across the treatment spectrum for EGFR exon 20 insertion mutations.
Furthermore, considering the overall market size, EGFR exon 20 insertion mutations represent only 2% to 5% of all EGFR-mutant NSCLC cases, resulting in a relatively small patient population. Therefore, if Fumeitinib's approved indication remains limited to second-line treatment, its addressable patient population would be even narrower, potentially imposing a low ceiling on its commercial potential and making it challenging to serve as a core growth driver for the company.
Comments